Management repeatedly pointed to the Center for Medicare and Medicaid Innovation (CMMI) pilot program as a key growth opportunity. Morachnick said that, under the pilot, seniors can gain access to “science-backed CBD products through a federally authorized Medicare pilot,” and that CMS recently issued additional guidance establishing the Substance Access Beneficiary Engagement Incentive (Substance Access BEI) as the mechanism for the program.In response to analyst questions about BAT’s ownership, Lind said ...

Regulatory Changes - The industry is experiencing a massive shift, potentially the largest in the last 50 years, due to the rescheduling of cannabis [3] - Cannabis is being reclassified from a Schedule 1 drug to a Schedule 3 drug, aligning it with substances like Tylenol with codeine or steroids [2] - This rescheduling is expected to increase access to medical research and attract more investment into the cannabis industry [2] - Companies selling cannabis may benefit from new opportunities to claim basic tax deductions that were previously unavailable [2] Healthcare Access - Dr Oz is introducing a Medicare pilot program to provide eligible seniors with access to cannabis [3] Market Impact - Cannabis stocks are reacting positively to the news [3]